FOXO4-DRI

Preclinical only Anti-Aging & Longevity 2 sources

FOXO4-DRI is an engineered peptide designed to selectively induce apoptosis (programmed cell death) in senescent cells. Research in animal models suggests it can clear these 'zombie cells' by disrupting the interaction between the FOXO4 and p53 proteins, potentially reversing signs of aging and restoring tissue function.

01Dosing reference

Amount

1-3 mg/day (theoretical research dose)

Frequency

Every other day

Cycle

Short bursts (e.g., 3 doses over a week) followed by long breaks

Reference figures, not a recommendationThese values reflect amounts described in the literature and vendor documentation this database indexes. Use the reconstitution calculator to convert them into syringe units.

02Mechanism of action

FOXO4-p53 Interaction Disruption

The peptide binds to p53, preventing it from interacting with FOXO4, a protein that keeps senescent cells alive.

Nuclear Exclusion of p53

Without FOXO4 holding it in the nucleus, p53 moves to the mitochondria.

Targeted Apoptosis

In the mitochondria, p53 triggers apoptosis specifically in senescent cells, sparing healthy cells.

03Human evidence

Lack of clinical trials

Currently, there are no published human clinical trials evaluating the safety or efficacy of FOXO4-DRI in humans. All data is derived from animal or cell culture models.

04Preclinical evidence

Reversal of aging signs in mice

In naturally aged mice and fast-aging mouse models, FOXO4-DRI restored fitness, fur density, and renal function.

Selective clearance of senescent cells

In vitro studies showed the peptide selectively killed senescent human fibroblasts while leaving healthy, dividing cells unharmed.

05What is known vs. unknown

Reasonably established

FOXO4-DRI acts as a senolytic, meaning it targets and destroys senescent cells.
It works by interfering with the FOXO4-p53 protein interaction.
Animal studies show improvements in physical fitness, kidney function, and hair growth after treatment.
It uses a D-retro-inverso (DRI) structure to resist degradation by enzymes, increasing its stability.

Unknowns & limits

The long-term effects of clearing senescent cells in humans are not fully understood.
Optimal dosing, safety, and potential off-target effects in humans remain completely unknown.
It is unclear if the benefits observed in mice will translate to human aging or age-related diseases.

06Safety & regulatory context

Regulatory statusFOXO4-DRI is an experimental research chemical and is not approved by the FDA or any regulatory body for human use. Because it has not undergone human clinical trials, its safety profile, potential side effects, and contraindications in humans are unknown. In animal studies, it appeared well-tolerated at specific doses, but interfering with p53—a major tumor suppressor protein—carries theoretical risks that require extensive investigation.

07Compared with Dasatinib and Quercetin (D+Q)

FOXO4-DRI vs. Dasatinib and Quercetin (D+Q)

Key difference

FOXO4-DRI is a targeted peptide that specifically disrupts FOXO4-p53, whereas D+Q is a combination of a cancer drug and a flavonoid that acts as a broader, less specific senolytic.

When researchers discuss each

Researchers discuss FOXO4-DRI when exploring highly targeted, peptide-based senolytics, while D+Q is discussed as a first-generation senolytic combination that has already entered early human trials.

08Glossary

Senescent Cells

Cells that have stopped dividing but do not die, often secreting inflammatory molecules that contribute to aging and disease.

Senolytic

A class of compounds that selectively induce death in senescent cells.

Apoptosis

The process of programmed cell death, which is a normal and controlled part of an organism's growth or development.

D-Retro-Inverso (DRI)

A peptide modification where the amino acid sequence is reversed and uses D-amino acids instead of natural L-amino acids, making it highly resistant to breakdown in the body.

09Knowledge check

Q1What is the primary mechanism of action for FOXO4-DRI?

Q2What type of cells does FOXO4-DRI specifically target?

Q3Which statement best describes the human evidence supporting FOXO4-DRI?

Q4According to the dossier, what key difference distinguishes FOXO4-DRI from the Dasatinib + Quercetin (D+Q) combination?

Q5Which regulatory or safety statement about FOXO4-DRI is supported by the dossier?

10Sources

More in Anti-Aging & Longevity

See all

Epitalon

Anti-Aging & Longevity

Human clinical

Epitalon is a synthetic tetrapeptide designed to mimic the effects of epithalamin, a natural polypeptide produced in the pineal gland. Research suggests it can activate telomerase, elongate telomeres, regulate melatonin production, and potentially extend lifespan in animal models.

5-10 mg/day

SS-31 (Elamipretide)

Anti-Aging & Longevity

Human clinical

SS-31, also known as elamipretide, is a mitochondria-targeted peptide that binds to cardiolipin in the inner mitochondrial membrane. It helps restore mitochondrial function, reduce oxidative stress, and improve cellular energy production. Research has heavily focused on its potential for treating heart failure, mitochondrial myopathies, and age-related cellular decline.

2-4 mg/day

Glutathione

Anti-Aging & Longevity

Human clinical

Glutathione is a powerful tripeptide naturally produced in the body, acting as the 'master antioxidant'. Research shows it plays a critical role in neutralizing free radicals, detoxifying harmful compounds, and supporting immune function. Studies are exploring its benefits for skin health, liver function, and mitigating age-related oxidative stress.

200-600 mg/day (SubQ/IM) or 500-1000 mg (Liposomal Oral)

Research and educational use onlyNothing on this site is medical advice, a prescription, or a recommendation for human use. Compounds documented here are research chemicals. Consult a qualified clinician before making any health decision.